Dyno Therapeutics

Dyno Therapeutics is a VC-backed biotech startup based in Cambridge, Massachusetts. The company develops DNA technologies and machine learning to engineer adeno-associated Virus (AAV) capsids for the effective delivery of gene therapies.

Founded in 2018 by a team of scientists that includes George Church, Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT).

Dyno Therapeutics' AI-powered approach to gene therapy uses machine learning and quantitative high-throughput in vivo experimentation. They aim to invent new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

The company emerged from stealth mode on May 11th, 2020, announcing its proprietary platform, CapsidMap. Dyno CEO and Co-Founder Eric Kelsic stated

At Dyno, we see a vast opportunity to expand the treatment landscape for gene therapies. The success of gene therapy relies on the ability of vectors to safely and precisely deliver a gene to the intended target cells and tissues. Our approach addresses the major limitations of naturally occurring AAV vectors and creates optimized, disease-specific vectors for gene therapies with great curative potential. Our portfolio of R&D programs and newly-announced collaborations with leading gene therapy developers reflect the applicability of our AI-powered approach to improve treatments for patients and expand the number of treatable diseases with gene therapies.

Dyno Therapeutics has announced partnerships with gene therapy companies Novartis and Sarepta Therapeutics.

Dyno Therapeutics raised $9M in Seed round funding on May 11, 2020. Lead investors were Polaris Partners & CRV.